Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Journal
Frontiers in oncology
Journal Volume
13
Date Issued
2023
Author(s)
Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for advanced EGFR-mutant non-small-cell lung cancer (NSCLC) patients. However, factors associated with outcomes after progression on first-line therapy are seldom investigated.
Subjects
epidermal growth factor receptor-tyrosine kinase inhibitor; neutrophil-to-lymphocyte ratio; non-small-cell lung cancer; osimertinib; re-biopsy; second-line
Type
journal article